Evidence map›Paper›PMID 34496895›Full record

ArticleRadiation oncology (London, England)2021

Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma.

Johannes Gollrad, Christopher Rabsahl, Aline-Isabel Riechardt, Jens Heufelder, Andrea Stroux, Ute Goerling, Antonia Joussen, Volker Budach, Dirk Boehmer

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Johannes GollradDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany. johannes.gollrad@charite.de.ORCID http://orcid.org/0000-0003-0853-144X
Christopher RabsahlDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Aline-Isabel RiechardtDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jens HeufelderDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Andrea StrouxInstitute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Ute GoerlingDepartment of Psycho-Oncology, CCCC, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Antonia JoussenDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Volker BudachDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Dirk BoehmerDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProton beam therapy is a well-established treatment option for patients with uveal melanoma (UM). The treatment procedure, in general, includes placing radiopaque clips to ensure exact eye-positioning during radiotherapy, followed by the delivery of proton irradiation. The short-term burden associated with proton therapy in patients with UM has rarely been addressed. In this prospective study, we investigated the physiological and psychological aspects of proton therapy that might affect the well-being of patients during the different stages of treatment.

methodsDuring the treatment procedure, we conducted longitudinal assessments of the Quality of life (QOL), organ-specific symptoms, and psychological aspects in patients with UM with three questionnaires (EORTC QLQ-C30, EORTC QLQ-OPT30, and GAD-7). Patients completed questionnaires before clip surgery (T0), before proton therapy (T1), after completing treatment (T2), and three months after treatment completion (T3). We also collected data on tumor characteristics and socio-demographics to identify potential risk factors associated with high treatment burdens.

resultsWe prospectively included 131 consecutive patients. Questionnaire data showed a significant, temporary decline in global QOL and an increase in eye-related symptoms, as a result of the clip surgery (T0-T1). After treatment completion (T2), global QOL improved gradually, and none of the eye-related symptoms significantly deteriorated over the course of proton therapy. The global QOL returned to baseline levels three months after treatment (T3). We identified baseline anxiety as an independent risk factor for experiencing an acute treatment-related burden. Furthermore, we found interactions between GAD7 and patient sex showing that anxiety had a more pronounced effect on QOL outcome in female patients.

conclusionThe short-term treatment-related burden of ocular proton therapy appeared to be largely associated with the preceding clip surgery, rather than the irradiation procedure. We found that anxiety was strongly associated with experiencing QOL issues during the treatment procedure. Our findings could contribute to the development of future strategies for improving the treatment process and psycho-oncologic patient care.

Indexed as

Quality of LifeAdultAgedAged, 80 and overFemaleHumansMaleMelanomaMiddle AgedProspective StudiesProton TherapyUveal MelanomaUveal NeoplasmsYoung AdultProton therapyQuality of lifeUveal melanoma

Identifiers

PMID34496895
PMCPMC8425039
OpenAlexW3198900417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.